R-333

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameR-333
Drug Alias NameR-932333R-333
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSpleen tyrosine kinase inhibitorsTyrosine-protein kinase JAK3 inhibitors
TargetsTyrosine-protein kinase JAK3Spleen tyrosine kinase
Therapy Area/IndicationsLupus Erythematosus, SystemicLupus Erythematosus, Discoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRigel Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRigel Pharmaceuticals
Active IndicationsN/A
Inactive IndicationsLupus Erythematosus, SystemicLupus Erythematosus, Discoid

Other Information

ATC CodeN/A
Related LinksN/A